FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326420146> ?p ?o ?g. }

• W2326420146 endingPage "715" @default.
• W2326420146 startingPage "715.13" @default.
• W2326420146 abstract "<h3>Background</h3> Management of patients with rheumatic diseases and at risk for developing NSAID-associated gastrointestinal (GI) events (symptoms and/or complications) varies not only across Europe but also within each country. <h3>Objectives</h3> The pan-European EVIDENCE study was designed to provide a real-life perspective of the current management of rheumatic diseases with NSAIDs in Europe, in terms of pain relief, side effects and preventive therapies among patients with GI risk factors. <h3>Methods</h3> EVIDENCE was a multicentre, prospective, observational (non-interventional) study of adult patients receiving NSAID therapy for rheumatoid arthritis (RA), osteoarthritis (OA) or ankylosing spondylitis (AS) (NCT01176682; study code: NIS-GEU-DUM-2010/1) [1]. Enrolled patients had at least one of the following GI risk factors (age >60 years, documented history of peptic ulcers or receiving concomitant treatment with any dose of acetylsalicylic acid [ASA], anticoagulants, selective serotonin reuptake inhibitors [SSRIs] or oral steroids) and had initiated NSAID therapy in the preceding 2-12 weeks. The primary endpoint was the incidence of pre-specified GI events (symptomatic and/or complicated) during 6 months’ follow-up. Complicated events were adjudicated and validated. Statistical analysis was descriptive. <h3>Results</h3> A total of 4149 patients (65% female, mean age 66 years) were enrolled (RA, 11%; OA, 85%; AS, 3%). 34% of patients had a documented history of GI events (most commonly gastritis, esophagitis, dyspepsia and heartburn). Use of ASA, anticoagulants, SSRIs and oral steroids was noted for 23%, 5%, 12% and 10% of patients, respectively. Diclofenac and ibuprofen were the most common index NSAIDs (33% and 22%, respectively). Among evaluable patients (n=4037), 9.9% (n=410) reported at least 1 GI event during 6 months’ follow-up, equating to an incidence rate of 16.9 events/100 patient-years. Incidence rates, by country, ranged from 8.3 (Switzerland) to 46.9 events/100 patient-years (Netherlands). Events were typically associated with the upper GI tract, most commonly dyspepsia, gastritis and heartburn (27%, 18% and 14% of events, respectively). Complicated GI events were uncommon (<1% of patients; incidence rate of 1.2 events/100 patient-years), as were cardiac events (<1%) and other complications (3.7%, including anaemia, pneumonia and osteoporosis). Overall, 62% of patients never received proton pump inhibitor therapy during follow-up. <h3>Conclusions</h3> The EVIDENCE study provides a comprehensive real-life view of the current management of patients with rheumatic diseases treated with NSAIDs, including low use of prevention therapies and the ongoing risk for developing GI events. Supported by AstraZeneca, Madrid, Spain <h3>References</h3> Lanas et al. Gut 2011;60 Suppl. 3:A153. <h3>Disclosure of Interest</h3> M. Boers Consultant for: Mundi, Novartis, Speakers Bureau: Merck, J. Nuevo Employee of: AstraZeneca, A. Lanas Consultant for: AstraZeneca, Pfizer, Speakers Bureau: AstraZeneca, Pfizer" @default.
• W2326420146 created "2016-06-24" @default.
• W2326420146 creator A5044831604 @default.
• W2326420146 creator A5074126079 @default.
• W2326420146 creator A5082620123 @default.
• W2326420146 date "2013-06-01" @default.
• W2326420146 modified "2023-10-03" @default.
• W2326420146 title "AB1360 Gastrointestinal events in patients receiving NSAIDs for rheumatic diseases in routine practice: The pan-european evidence study" @default.
• W2326420146 doi "https://doi.org/10.1136/annrheumdis-2012-eular.1354" @default.
• W2326420146 hasPublicationYear "2013" @default.
• W2326420146 type Work @default.
• W2326420146 sameAs 2326420146 @default.
• W2326420146 citedByCount "0" @default.
• W2326420146 crossrefType "journal-article" @default.
• W2326420146 hasAuthorship W2326420146A5044831604 @default.
• W2326420146 hasAuthorship W2326420146A5074126079 @default.
• W2326420146 hasAuthorship W2326420146A5082620123 @default.
• W2326420146 hasConcept C120665830 @default.
• W2326420146 hasConcept C121332964 @default.
• W2326420146 hasConcept C126322002 @default.
• W2326420146 hasConcept C142724271 @default.
• W2326420146 hasConcept C204787440 @default.
• W2326420146 hasConcept C2776164576 @default.
• W2326420146 hasConcept C2777402515 @default.
• W2326420146 hasConcept C2777575956 @default.
• W2326420146 hasConcept C2779384505 @default.
• W2326420146 hasConcept C2779826273 @default.
• W2326420146 hasConcept C61511704 @default.
• W2326420146 hasConcept C71924100 @default.
• W2326420146 hasConcept C98274493 @default.
• W2326420146 hasConceptScore W2326420146C120665830 @default.
• W2326420146 hasConceptScore W2326420146C121332964 @default.
• W2326420146 hasConceptScore W2326420146C126322002 @default.
• W2326420146 hasConceptScore W2326420146C142724271 @default.
• W2326420146 hasConceptScore W2326420146C204787440 @default.
• W2326420146 hasConceptScore W2326420146C2776164576 @default.
• W2326420146 hasConceptScore W2326420146C2777402515 @default.
• W2326420146 hasConceptScore W2326420146C2777575956 @default.
• W2326420146 hasConceptScore W2326420146C2779384505 @default.
• W2326420146 hasConceptScore W2326420146C2779826273 @default.
• W2326420146 hasConceptScore W2326420146C61511704 @default.
• W2326420146 hasConceptScore W2326420146C71924100 @default.
• W2326420146 hasConceptScore W2326420146C98274493 @default.
• W2326420146 hasIssue "Suppl 3" @default.
• W2326420146 hasLocation W23264201461 @default.
• W2326420146 hasOpenAccess W2326420146 @default.
• W2326420146 hasPrimaryLocation W23264201461 @default.
• W2326420146 hasRelatedWork W1566553263 @default.
• W2326420146 hasRelatedWork W1795199956 @default.
• W2326420146 hasRelatedWork W1973161046 @default.
• W2326420146 hasRelatedWork W1984423025 @default.
• W2326420146 hasRelatedWork W2009326021 @default.
• W2326420146 hasRelatedWork W2016790082 @default.
• W2326420146 hasRelatedWork W2051715529 @default.
• W2326420146 hasRelatedWork W2074359641 @default.
• W2326420146 hasRelatedWork W2137648653 @default.
• W2326420146 hasRelatedWork W2318123293 @default.
• W2326420146 hasRelatedWork W2330421173 @default.
• W2326420146 hasRelatedWork W2330575935 @default.
• W2326420146 hasRelatedWork W2551487126 @default.
• W2326420146 hasRelatedWork W2755712429 @default.
• W2326420146 hasRelatedWork W2784098943 @default.
• W2326420146 hasRelatedWork W2801778889 @default.
• W2326420146 hasRelatedWork W2947871458 @default.
• W2326420146 hasRelatedWork W3093950033 @default.
• W2326420146 hasRelatedWork W3131316834 @default.
• W2326420146 hasRelatedWork W3137471689 @default.
• W2326420146 hasVolume "71" @default.
• W2326420146 isParatext "false" @default.
• W2326420146 isRetracted "false" @default.
• W2326420146 magId "2326420146" @default.
• W2326420146 workType "article" @default.